DK169952B1 - DNA-sekvens, epidermalt udtrykkelsesmiddel, fremgangsmåde til fremstilling af et rekombinant polypeptid, plasmid og værtscelle, som er transformeret med DNA-sekvensen - Google Patents

DNA-sekvens, epidermalt udtrykkelsesmiddel, fremgangsmåde til fremstilling af et rekombinant polypeptid, plasmid og værtscelle, som er transformeret med DNA-sekvensen Download PDF

Info

Publication number: DK169952B1
Authority: DK; Denmark
Prior art keywords: yeast; sequence; dna sequence; polypeptide; gene
Prior art date: 1983-01-12

Application number

DK577883A

Other languages

Danish (da)

English (en)

Other versions

DK577883D0 (da

DK577883A (da

Inventor

Anthony John Brake

Original Assignee

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-01-12

Filing date

1983-12-15

Publication date

1995-04-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27038554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK169952(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1983-12-15 Application filed by Chiron Corp filed Critical Chiron Corp

1983-12-15 Publication of DK577883D0 publication Critical patent/DK577883D0/da

1984-07-13 Publication of DK577883A publication Critical patent/DK577883A/da

1995-04-10 Application granted granted Critical

1995-04-10 Publication of DK169952B1 publication Critical patent/DK169952B1/da

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 69
229920001184 polypeptide Polymers 0.000 title claims description 67
102000004196 processed proteins & peptides Human genes 0.000 title claims description 67
238000000034 method Methods 0.000 title claims description 48
239000013612 plasmid Substances 0.000 title claims description 39
108091028043 Nucleic acid sequence Proteins 0.000 title claims description 36
108090000623 proteins and genes Proteins 0.000 claims description 76
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 47
102000004169 proteins and genes Human genes 0.000 claims description 35
230000008569 process Effects 0.000 claims description 31
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 claims description 27
239000012634 fragment Substances 0.000 claims description 22
150000001413 amino acids Chemical group 0.000 claims description 21
230000028327 secretion Effects 0.000 claims description 20
238000004519 manufacturing process Methods 0.000 claims description 19
108020004705 Codon Proteins 0.000 claims description 14
210000004027 cell Anatomy 0.000 claims description 14
102400001368 Epidermal growth factor Human genes 0.000 claims description 12
101800003838 Epidermal growth factor Proteins 0.000 claims description 12
229940116977 epidermal growth factor Drugs 0.000 claims description 12
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 11
239000001963 growth medium Substances 0.000 claims description 7
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims description 7
-1 calcidonin Proteins 0.000 claims description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
230000002103 transcriptional effect Effects 0.000 claims description 6
239000002243 precursor Substances 0.000 claims description 5
OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims description 4
238000003780 insertion Methods 0.000 claims description 4
230000037431 insertion Effects 0.000 claims description 4
230000010076 replication Effects 0.000 claims description 4
102000009027 Albumins Human genes 0.000 claims description 3
108010088751 Albumins Proteins 0.000 claims description 3
239000004475 Arginine Substances 0.000 claims description 3
101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 claims description 3
102000004877 Insulin Human genes 0.000 claims description 3
108090001061 Insulin Proteins 0.000 claims description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
102000014150 Interferons Human genes 0.000 claims description 3
108010050904 Interferons Proteins 0.000 claims description 3
108090000783 Renin Proteins 0.000 claims description 3
102100028255 Renin Human genes 0.000 claims description 3
102000013275 Somatomedins Human genes 0.000 claims description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
229940116978 human epidermal growth factor Drugs 0.000 claims description 3
229940125396 insulin Drugs 0.000 claims description 3
210000005253 yeast cell Anatomy 0.000 claims description 3
101710089839 Dipeptidyl aminopeptidase A Proteins 0.000 claims description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
239000004472 Lysine Substances 0.000 claims description 2
238000012423 maintenance Methods 0.000 claims description 2
125000006850 spacer group Chemical group 0.000 claims description 2
102000018997 Growth Hormone Human genes 0.000 claims 2
108010051696 Growth Hormone Proteins 0.000 claims 2
239000000122 growth hormone Substances 0.000 claims 2
229940079322 interferon Drugs 0.000 claims 2
241000235070 Saccharomyces Species 0.000 claims 1
230000005030 transcription termination Effects 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 23
239000000047 product Substances 0.000 description 19
235000001014 amino acid Nutrition 0.000 description 18
102000004190 Enzymes Human genes 0.000 description 11
108090000790 Enzymes Proteins 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
238000003776 cleavage reaction Methods 0.000 description 8
230000007017 scission Effects 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 6
239000002585 base Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
108091026890 Coding region Proteins 0.000 description 5
108091081024 Start codon Proteins 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
239000002773 nucleotide Substances 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
108010016626 Dipeptides Proteins 0.000 description 4
101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
210000002950 fibroblast Anatomy 0.000 description 4
230000004927 fusion Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
239000013598 vector Substances 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000004594 DNA Polymerase I Human genes 0.000 description 3
108010017826 DNA Polymerase I Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
101150084418 EGF gene Proteins 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
108010049140 Endorphins Proteins 0.000 description 2
102000009025 Endorphins Human genes 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000001627 detrimental effect Effects 0.000 description 2
238000011049 filling Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
108010049041 glutamylalanine Proteins 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
230000035800 maturation Effects 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
210000004897 n-terminal region Anatomy 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
235000019833 protease Nutrition 0.000 description 2
238000000746 purification Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
NFUCNAREVSTFNC-UHFFFAOYSA-N 2-(5-oxo-1-phenyl-2-sulfanylideneimidazolidin-4-yl)acetic acid Chemical compound O=C1C(CC(=O)O)NC(=S)N1C1=CC=CC=C1 NFUCNAREVSTFNC-UHFFFAOYSA-N 0.000 description 1
102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
ULKNJYDXLYMGFB-UHFFFAOYSA-N 3-(5-oxo-1-phenyl-2-sulfanylideneimidazolidin-4-yl)propanoic acid Chemical compound O=C1C(CCC(=O)O)NC(=S)N1C1=CC=CC=C1 ULKNJYDXLYMGFB-UHFFFAOYSA-N 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
108010065372 Dynorphins Proteins 0.000 description 1
101100223032 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) dapB gene Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
241001131785 Escherichia coli HB101 Species 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 1
101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
102400000050 Oxytocin Human genes 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000001105 Phosphofructokinases Human genes 0.000 description 1
108010069341 Phosphofructokinases Proteins 0.000 description 1
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
102100024622 Proenkephalin-B Human genes 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
101150028158 STE13 gene Proteins 0.000 description 1
NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
101150018117 cobB gene Proteins 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
239000011521 glass Substances 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
108010056929 lyticase Proteins 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
101150089009 sir2 gene Proteins 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)

DK577883A 1983-01-12 1983-12-15 DNA-sekvens, epidermalt udtrykkelsesmiddel, fremgangsmåde til fremstilling af et rekombinant polypeptid, plasmid og værtscelle, som er transformeret med DNA-sekvensen DK169952B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US45732583A	1983-01-12	1983-01-12
US45732583		1983-01-12
US52290983A	1983-08-12	1983-08-12
US52290983		1983-08-12

Publications (3)

Publication Number	Publication Date
DK577883D0 DK577883D0 (da)	1983-12-15
DK577883A DK577883A (da)	1984-07-13
DK169952B1 true DK169952B1 (da)	1995-04-10

Family

ID=27038554

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK577883A DK169952B1 (da)	1983-01-12	1983-12-15	DNA-sekvens, epidermalt udtrykkelsesmiddel, fremgangsmåde til fremstilling af et rekombinant polypeptid, plasmid og værtscelle, som er transformeret med DNA-sekvensen

Country Status (5)

Country	Link
EP (1)	EP0116201B1 (de)
JP (2)	JPH0779699B2 (de)
CA (1)	CA1341297C (de)
DE (1)	DE3382547D1 (de)
DK (1)	DK169952B1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4943529A (en)	1982-05-19	1990-07-24	Gist-Brocades Nv	Kluyveromyces as a host strain
JPS60501140A (ja) *	1983-04-22	1985-07-25	アムジエン	酵母による外因性ポリペプチドの分泌
US7198919B1 (en)	1983-04-25	2007-04-03	Genentech, Inc.	Use of alpha factor sequences in yeast expression systems
NZ207842A (en)	1983-04-25	1988-02-12	Chiron Corp	Production of human insulin-like growth factor (igf) using cdna
NZ207926A (en) *	1983-04-25	1988-04-29	Genentech Inc	Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
IL71991A (en)	1983-06-06	1994-05-30	Genentech Inc	Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US5639639A (en) *	1983-11-02	1997-06-17	Genzyme Corporation	Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
JPS61502795A (ja) *	1984-07-09	1986-12-04	レモント，ジェフリ−・エフ	酵母クロ−ニング　ビ−クル
EP0188555A4 (de) *	1984-07-09	1988-04-18	Integrated Genetics Inc	Klonierungsvektor für hefe.
DE3587205T2 (de) *	1984-07-30	1993-08-26	Wakunaga Seiyaku Kk	Verfahren zur herstellung eines proteins und dafuer zu verwendender vektor, rekombinante dns und transformierte zelle.
JPS61503002A (ja) *	1984-07-31	1986-12-25	アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ	酵母クロ−ニングベクタ−
WO1986001515A1 (en) *	1984-08-29	1986-03-13	Chiron Corporation	Expression of human connective tissue activator and related peptides
EP0487116B1 (de) *	1984-10-12	1999-12-29	ZymoGenetics, Inc.	Von Blutplättchen abstammende biologisch aktive Analoga eines Wachstumsfaktors in eukaryotischen Zellen
US5187263A (en) *	1984-10-12	1993-02-16	Zymogenetics, Inc.	Expression of biologically active PDGE analogs in eucaryotic cells
US5498600A (en) *	1984-10-12	1996-03-12	Zymogenetics, Inc.	Biologically active mosaic proteins
ATE73345T1 (de) *	1984-10-19	1992-03-15	Chiron Corp	Anregung zur heilung einer wunde mittels menschlichen hautwachstumsfaktors hergestellt durch rekombinant-dns.
AU588819B2 (en) *	1984-10-29	1989-09-28	Immunex Corporation	Cloning of human granulocyte-macrophage colony stimulating factor gene
US7285271B1 (en)	1984-10-31	2007-10-23	Novartis Vaccines And Diagnostics, Inc.	Antigenic composition comprising an HIV gag or env polypeptide
US7273695B1 (en)	1984-10-31	2007-09-25	Novartis Vaccines And Diagnostics, Inc.	HIV immunoassays using synthetic envelope polypeptides
CA1341423C (en)	1984-10-31	2003-03-04	Paul A. Luciw	Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US5045633A (en) *	1985-02-25	1991-09-03	Zymogenetics, Inc.	Expression of biologically active PDGF analogs in eucaryotic cells
DE3515336C2 (de) *	1985-04-27	1994-01-20	Boehringer Ingelheim Int	Verfahren zur Herstellung und Reinigung von â-Interferon
FR2593518B1 (fr) *	1985-05-02	1989-09-08	Transgene Sa	Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
US5821079A (en) *	1985-05-02	1998-10-13	Transgene S.A.	Vectors for the expression and secretion of hirudin by transformed yeasts
IL78775A (en) *	1985-05-15	1992-06-21	Biotech Australia Pty Ltd	Oral vaccines
JPS61271988A (ja) *	1985-05-27	1986-12-02	Agency Of Ind Science & Technol	プラスミド
JPS6236183A (ja) *	1985-06-20	1987-02-17	ザ・サルク・インステイチユ−ト・バイオテクノロジ−／インダストリアル・アソシエイツ・インコ−ポレ−テツド	サツカロミセス・セレビシエからのポリペプチドの発現および分泌
GB8529014D0 (en) *	1985-11-25	1986-01-02	Biogen Nv	Enhanced secretion of heterologous proteins
US5024941A (en) *	1985-12-18	1991-06-18	Biotechnica International, Inc.	Expression and secretion vector for yeast containing a glucoamylase signal sequence
EP0234862A3 (de) *	1986-02-28	1988-10-05	Merck & Co. Inc.	Expression rekombinanter Proteine in Hefe
EP0234871A3 (de) *	1986-02-28	1988-10-12	Merck & Co. Inc.	Regulierbare Expression rekombinanter Proteine in Hefe
US5010182A (en) *	1987-07-28	1991-04-23	Chiron Corporation	DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AR247761A1 (es) *	1987-07-28	1995-03-31	Gist Brocades Nv	Metodo para producir un polipeptido en una celula hospedante de kluyveromyces, dicha celula hospedante transformada y secuencia a adn empleada
US7442525B1 (en)	1987-12-24	2008-10-28	Novartis Vaccines And Diagnostics, Inc.	Method for expressing HIV polypeptides
CA1340772C (en)	1987-12-30	1999-09-28	Patricia Tekamp-Olson	Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US6018026A (en) *	1988-01-22	2000-01-25	Zymogenetics, Inc.	Biologically active dimerized and multimerized polypeptide fusions
DE68926888T2 (de) *	1988-01-22	1997-01-09	Zymogenetics Inc	Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5567584A (en) *	1988-01-22	1996-10-22	Zymogenetics, Inc.	Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) *	1988-01-22	1998-05-12	Zymogenetics, Inc.	Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
JPH0771509B2 (ja) *	1988-07-12	1995-08-02	工業技術院長	ヒトβ−ＮＧＦの発現法
DE68928124T2 (de)	1988-09-02	1997-10-16	Chiron Corp., Emeryville, Calif.	Makrophagenabgeleiteter entzündungsmediator(mip-2)
US6194140B1 (en)	1990-04-04	2001-02-27	Chiron Corporation	HCV NS3 protein fragments having helicase activity and improved solubility
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AU5013893A (en) *	1992-08-14	1994-03-15	Rockefeller University, The	Herpesviral defective vector with rat preproenkephalin gene promoter
JP2609515B2 (ja) *	1993-04-26	1997-05-14	ダイウォンファーマシューティカルカンパニー，リミテッド	ヒト上皮成長因子をコードする新規な遺伝子およびその製造方法
WO1994026306A1 (en)	1993-05-12	1994-11-24	Chiron Corporation	Conserved motif of hepatitis c virus e2/ns1 region
US6500645B1 (en)	1994-06-17	2002-12-31	Novo Nordisk A/S	N-terminally extended proteins expressed in yeast
ZA9610456B (en) *	1995-12-20	1997-06-20	Novo Nordisk As	N-terminally extended proteins expressed in yeast
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
DE69740176D1 (de)	1996-03-01	2011-05-26	Novo Nordisk As	Appetithemmendes Peptid, Zusammensetzung und Verwendung
US6087128A (en)	1998-02-12	2000-07-11	Ndsu Research Foundation	DNA encoding an avian E. coli iss
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2213743A1 (de)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albuminfusionsproteine
US7507413B2 (en)	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2004024885A2 (en)	2002-09-13	2004-03-25	Cornell Research Foundation, Inc.	Using mutations to improve aspergillus phytases
DE60335602D1 (de)	2002-12-18	2011-02-17	Roche Diagnostics Gmbh	Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
AU2006291780B2 (en)	2005-09-14	2011-12-08	F. Hoffmann-La Roche Ag	Cleavage of precursors of insulins by a variant of trypsin
US20100021967A1 (en) *	2006-10-24	2010-01-28	Novozymes A/S	Alpha Factor Signal Peptide For Producing a Polypeptide
EA037848B1 (ru)	2016-07-14	2021-05-27	Общество С Ограниченной Ответственностью "Биохимический Агент"	Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты)
WO2022049409A1 (en)	2020-09-02	2022-03-10	Sia Terragen	Express diagnosticum for sars-cov-2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4411994A (en) *	1978-06-08	1983-10-25	The President And Fellows Of Harvard College	Protein synthesis
US4338397A (en) *	1980-04-11	1982-07-06	President And Fellows Of Harvard College	Mature protein synthesis
FI64813C (fi) *	1980-12-31	1984-01-10	Ilkka Antero Palva	Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer
NZ199722A (en) *	1981-02-25	1985-12-13	Genentech Inc	Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
IE53517B1 (en) *	1981-06-17	1988-12-07	Celltech Ltd	Process for the production of a polypeptide
US4615974A (en) *	1981-08-25	1986-10-07	Celltech Limited	Yeast expression vectors
NZ201705A (en) *	1981-08-31	1986-03-14	Genentech Inc	Recombinant dna method for production of hepatitis b surface antigen in yeast
US4775622A (en) *	1982-03-08	1988-10-04	Genentech, Inc.	Expression, processing and secretion of heterologous protein by yeast

1983
- 1983-10-26 EP EP83306507A patent/EP0116201B1/de not_active Expired - Lifetime
- 1983-10-26 DE DE8383306507T patent/DE3382547D1/de not_active Expired - Lifetime
- 1983-11-18 CA CA 441501 patent/CA1341297C/en not_active Expired - Fee Related
- 1983-12-15 DK DK577883A patent/DK169952B1/da not_active IP Right Cessation
1984
- 1984-01-09 JP JP59000939A patent/JPH0779699B2/ja not_active Expired - Lifetime
1990
- 1990-03-14 JP JP2061304A patent/JPH0779710B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH0779710B2 (ja)	1995-08-30
EP0116201A1 (de)	1984-08-22
DK577883D0 (da)	1983-12-15
JPH0779699B2 (ja)	1995-08-30
EP0116201B1 (de)	1992-04-22
DE3382547D1 (de)	1992-05-27
JPS59132892A (ja)	1984-07-31
DK577883A (da)	1984-07-13
JPH0372893A (ja)	1991-03-28
CA1341297C (en)	2001-09-25

Legal Events

Date	Code	Title	Description
1995-04-10	B1	Patent granted (law 1993)
2004-01-05	PUP	Patent expired

Publication	Publication Date	Title
DK169952B1 (da)	1995-04-10	DNA-sekvens, epidermalt udtrykkelsesmiddel, fremgangsmåde til fremstilling af et rekombinant polypeptid, plasmid og værtscelle, som er transformeret med DNA-sekvensen
US4870008A (en)	1989-09-26	Secretory expression in eukaryotes
Clare et al.	1991	Production of mouse epidermal growth factor in yeast: high-level secretion using Pichia pastoris strains containing multiple gene copies
JP3730255B2 (ja)	2005-12-21	イーストにおいて発現されたｎ末端に伸長した蛋白質
AU660161B2 (en)	1995-06-15	A method of constructing synthetic leader sequences
US5759802A (en)	1998-06-02	Production of human serum alubumin A
EP0792367B1 (de)	2001-10-17	Für das yap3 signalpeptid kodierendes dna-konstrukt
FI100995B (fi)	1998-03-31	Hiivan alfa-faktoriekspressiojärjestelmä
JP2708518B2 (ja)	1998-02-04	合成酵母リーダーペプチド
EP0341215B1 (de)	1995-06-21	Herstellung von Proteinen
NO174351B (no)	1994-01-10	Fremgangsmaate for fremstilling av human insulinforloeper samt DNA-sekvens og vektor til anvendelse av fremgangsmaaten
CZ364196A3 (en)	1997-05-14	Dna expression cassette, yeast expression vector, yeast cell and process for preparing a polypeptide in yeast
EP0329684A4 (de)	1989-10-25	Komposit-hefevektoren.
JP4187796B2 (ja)	2008-11-26	酵母で発現されたｎ末端伸長タンパク質
EP0868523B1 (de)	2005-05-18	Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
KR970005584B1 (ko)	1997-04-18	폴리 펩타이드의 개선된 제조방법
FI96121B (fi)	1996-01-31	DNA-rakenne ja menetelmä heterologisen proteiinin tuottamiseksi
EP0188555A4 (de)	1988-04-18	Klonierungsvektor für hefe.